Highnoon Laboratories (HINOON) Stock Overview
Manufactures, imports, sells, exports, and markets pharmaceutical and allied consumer products. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for HINOON from our risk checks.
HINOON Community Fair Values
Create NarrativeSee what 25 others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Highnoon Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | PK₨1,164.09 |
| 52 Week High | PK₨1,241.00 |
| 52 Week Low | PK₨688.90 |
| Beta | -0.0057 |
| 1 Month Change | -0.60% |
| 3 Month Change | 17.22% |
| 1 Year Change | 66.50% |
| 3 Year Change | 178.02% |
| 5 Year Change | 191.62% |
| Change since IPO | 32,603.26% |
Recent News & Updates
Recent updates
Shareholder Returns
| HINOON | PK Pharmaceuticals | PK Market | |
|---|---|---|---|
| 7D | 1.2% | 0.6% | 3.0% |
| 1Y | 66.5% | 91.6% | 78.3% |
Return vs Industry: HINOON underperformed the PK Pharmaceuticals industry which returned 90.9% over the past year.
Return vs Market: HINOON underperformed the PK Market which returned 80.2% over the past year.
Price Volatility
| HINOON volatility | |
|---|---|
| HINOON Average Weekly Movement | 2.8% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in PK Market | 8.7% |
| 10% least volatile stocks in PK Market | 3.3% |
Stable Share Price: HINOON has not had significant price volatility in the past 3 months compared to the PK market.
Volatility Over Time: HINOON's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 2,376 | Adeel Haider | www.highnoon-labs.com |
Highnoon Laboratories Limited, together with its subsidiaries, manufactures, imports, sells, exports, and markets pharmaceutical and allied consumer products. It offers products in various therapeutic areas, including allergy, anti-infective, cardiology, gastroenterology, metabolic, musculoskeletal, obstetrics and gynaecology, paediatrics, allergy, respiratory, and urology; and generic products under various brands. The company operates in Pakistan, Afghanistan, the United Arab Emirates, France, Kenya, Iraq, Cambodia, Tanzania, Dubai, Sudan, and internationally.
Highnoon Laboratories Limited Fundamentals Summary
| HINOON fundamental statistics | |
|---|---|
| Market cap | PK₨61.68b |
| Earnings (TTM) | PK₨3.52b |
| Revenue (TTM) | PK₨25.78b |
Is HINOON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HINOON income statement (TTM) | |
|---|---|
| Revenue | PK₨25.78b |
| Cost of Revenue | PK₨11.99b |
| Gross Profit | PK₨13.79b |
| Other Expenses | PK₨10.27b |
| Earnings | PK₨3.52b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 66.38 |
| Gross Margin | 53.50% |
| Net Profit Margin | 13.65% |
| Debt/Equity Ratio | 4.0% |
How did HINOON perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 11:48 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Highnoon Laboratories Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Arvind Anand | Fortune Securities Limited |